DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20190657

Comparative analysis of safety and efficacy of cefotaxime/sulbactam verses piperacillin/tazobactam combinations in the treatment of complicated urinary tract infections

Sohil P. Makwana, Manish N. Solanki

Abstract


Background: Complicated UTIs (cUTIs) are leading causes of the gram negative bacteraemia. The objective of this study was to compare efficacy and safety Cefotaxime/ Sulbactam (CTS) and Piperacillin/ Tazobactam (PT) combinations in complicated Urinary Tract Infections.

Methods: Total 80 patients admitted in the hospital due to cUTI were enrolled. 31 patients were given CTS while 49 patients were given PT. Clinical symptoms were registered and scored as mild (1) moderate (2) or severe (3). The follow-up of were done daily till the patient is discharged. Thereafter, one follow up visit was done within 4 to 9 days of after discharge, termed as test of cure (TOC), and, one late follow up visit after 6 to 8 weeks was done, known as late follow up visit (LFU). Clinical assessments and microbiological analysis were done at the time of TOC and LFU.

Results: At TOC visit, in CTS and PT groups, clinical scores were 1.25±3.47 and 0.86±2.35, respectively (p<0.005). Rate of clinical improvement at TOC visit was 92.00% and 92.68% while microbiological clearance was 84.00% and 87.80% with CTS and PT groups respectively. At LFU visit, clinical scores CTS and PT in groups were 1.30±3.56 and 1.32±3.37, respectively, suggesting significant improvement from baseline (p<0.005). Clinical cure rate at LFU visit was 88.00% and 87.80% while microbiological cure rate at LFU visit was 76.00% and 82.91% in CTS and PT groups respectively.

Conclusions: Results suggest that both regimens have no significant difference for the treatment of cUTI. CTS and PT both are equally efficacious in treatment of cUTI.


Keywords


Complicated UTI, Cefotaxime, Piperacillin, Sulbactam, Tazobactam, UTI

Full Text:

PDF

References


Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med 1993;329:1328-34.

LE Nicolle, AMMI Canada Guidelines Committee. Complicated urinary tract infection in adults. Can J Infect Dis Med Microbiol. 2005;16(6):349-60.

Yildiz B, Kural N, Durmaz G, Yarar C, Ak I, Akcar N. Antibiotic resistance in children with complicated urinary tract infection. Saudi Med J. 2007;28(12):1850-4.

Peterson J, Kaul S, Khashab M, Fisher A, Kahn JB. Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006. Clin Ther. 2007;29(10):2215-21.

Donlan RM, Costerton JW. Biofilms: Survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15:167-93.

Mahesh E, Ramesh D, Indumathi VA, Punith K, Raj K, Anupama HA. Complicated Urinary Tract Infection in a Tertiary Care Center in South India. Al Ameen J Med Sci. 2010;3(2):120-7.

Stamm WE, Norrby SR. Urinary Tract Infections: Disease Panorama and Challenges J Infect Dis. 2001;183(Suppl 1):Sl-S4.

Ghedria, L Messaoudi A, Guediche MN. Profile of antimicrobial resistance of agents causing urinary tract infections in children. Tunis Med. 2004;82(3):299-305.

Mazzulli T. Resistance trends in urinary tract pathogens and impact on management. J Urol. 2002;168(4 Pt 2):1720-2.

Naber KG, Savov O, Salmen HC. Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections. Int J Antimicrob Agents. 2002;19:95-103.

Cox CE, Marbury TC, Pittman WG, Brown GL, Auerbach SM, Fox BC, et al. A randomized, doubleblind multicenter comparison of gatifloxacin vs ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. Clin Ther. 2002;24:223-36.

Durwood E. Nea, Complicated Urinary Tract Infections. Urol Clin N Am. 2008;35:13-22.

Naber KG. Experience with the new guidelines on evaluation of new anti-infective drugs for the treatment of urinary tract infections. Int J Antimicrob Agents. 1999;11(3-4):189.

Nicolle LE. A practical guide to the management of complicated urinary tract infection. Drugs. 1997;53:583-92.

Kallel H, Bahoul M, Ksibi H. Prevalence of hospital acquired infection in a Tunisian Hospital. Journal of Hospital, Infection. 2005;59(4):343-7.

Naber KG, Savov O, Salmen HC. Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections. Int J Antimicrob Agents. 2002;19:95-103.

Horowitz EA, Preheim LC, Safranek TJ, Pugsley MP, Sanders CC, Bittner MJ. Randomized, double-blind comparison of ceftazidime and moxalactam in complicated urinary tract infections. Antimicrob Agents Chemother. 1985;28:299-301.

Nishiura T. Clinical comparison of cefoperazone in complicated urinary tract infections using a double-blind method. Clin Ther. 1980;3:190-205.

Fang GD, Brennen C, Wagener M. Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study. Antimicrob. Agents Chemother. 1991;35:1849-55.